COMP <GO>
ACXP vs APRE // GROSS PROFIT MARGIN
Acurx Pharmaceuticals Inc. (NASDAQ) VS. Aprea Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ACXP 0
— APRE 2
■ METRIC PARITY
LAST: $1.07 (0.00%) • MKT CAP: $5.9M
gross-margins
—
LAST: $0.49 (-8.22%) • MKT CAP: $6.2M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACXP VS. APRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACXP | APRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.6 | 37.1 | -10.49 | APRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.9M | $6.2M | -$266.4K | APRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACXP REV | APRE REV | ACXP GROSS % | APRE GROSS % | ACXP FCF | APRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$6.8M | -$12.9M |
| FY 2024 | $0 | $0 | — | — | -$10.4M | -$13.6M |
| FY 2023 | $0 | $0 | — | — | -$9.8M | -$12.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACXP // BETA —
APRE // BETA —